Being JCV positive means your blood carries antibodies against JC virus (John Cunningham virus), a polyomavirus that silently infects a large share of the world’s population. For most people, this result has no health consequences whatsoever. The virus persists quietly in kidney tissue and certain immune cells without causing symptoms. The reason the test exists, and the reason your doctor likely ordered it, is a single rare but serious brain disease called progressive multifocal leukoencephalopathy, or PML, which can occur when JCV reactivates under conditions of severe immune suppression.
How Common Is JCV Infection
JCV is extraordinarily widespread. A systematic review of studies across multiple continents found that antibody prevalence in the general population ranges from roughly 50 to 90 percent, depending on the population sampled and the assay used.1PubMed Central. Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica A large meta-analysis looking specifically at healthy subjects found that seroprevalence rises with age: about 60 percent of adults aged 15 to 49 carry antibodies, climbing to roughly 65 percent among those over 50.2PLOS ONE. JC polyomavirus (JCV, HPyV2) seropositivity prevalence in healthy subjects: Systematic review and meta-analysis In practical terms, if you lined up ten adults at random, somewhere between five and seven of them would test JCV positive.
Primary infection typically happens during childhood or adolescence and produces no noticeable illness.3PubMed Central. Individuals infected with JC polyomavirus do not present detectable JC virus DNA in oropharyngeal fluids The exact way the virus spreads remains surprisingly unclear. Researchers have found JCV in sewage and environmental water, which supports the idea that contaminated water or food may be a transmission route.4PubMed. Role of the environment in the transmission of JC virus Family transmission also plays a role: one study found that roughly half of JCV-positive children carried strains matching those of their parents, suggesting that parent-to-child contact accounts for about half of all infections, with the remainder picked up from the broader environment.5PubMed Central. Parent-to-child transmission is relatively common in the spread of the human polyomavirus JC virus
Why the Test Matters
For the overwhelming majority of people who are JCV positive, the virus sits dormant in kidney tissue, bone marrow, and lymphoid organs and never causes trouble.6PubMed Central. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy The test becomes medically important when a person needs a treatment that deeply suppresses the immune system, because that is the circumstance under which JCV can wake up and cause PML.
PML most commonly occurs in three settings: advanced HIV infection, certain blood cancers, and in people with multiple sclerosis who take the drug natalizumab (brand name Tysabri).7Nature Reviews Neurology. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease Natalizumab is one of the most effective therapies for relapsing MS, but because it prevents immune cells from crossing into the brain, it creates exactly the kind of immune blind spot that allows JCV to reactivate there. If you are being tested for JCV antibodies, there is a good chance it is because your neurologist is either considering starting you on natalizumab or monitoring you while you take it.
Being JCV negative before starting natalizumab is reassuring: your risk of PML is very low. Being JCV positive does not mean you will develop PML. It means the virus is present and could, in theory, reactivate. How likely that is depends on additional factors, particularly how long you have been on the drug, whether you have used other immunosuppressants in the past, and the concentration of antibodies in your blood.
The Antibody Index and Risk Stratification
A simple positive-or-negative result is only the first step. For natalizumab-treated MS patients, the lab also reports a number called the anti-JCV antibody index, which reflects the level of antibodies in your blood. A higher index generally signals a higher risk of PML.8PubMed Central. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy In patients who had never used other immunosuppressants, the distribution of antibody index values was markedly higher in those who eventually developed PML than in those who did not.
Current risk-stratification guidelines use the antibody index alongside treatment duration and prior immunosuppressant use to produce an estimated PML risk. But these thresholds are imperfect. One analysis pointed out that patients with an index in the 0.6 to 0.9 range, sometimes categorized as lower risk, can in practice reach annual PML risks that are not as low as the algorithm suggests. A fatal case in Australia involved a patient whose index was only 0.7, and who had never used other immunosuppressants, yet developed PML after four years on the drug.9PubMed Central. Improving risk-stratification of natalizumab-associated PML That case is a reminder that the index helps sort risk into broad buckets but does not make individual predictions.
Still, the antibody index remains the best tool available. It has been shown to be highly sensitive at identifying patients who go on to develop PML, though its specificity is moderate, meaning it flags many patients who will never get the disease. One validation study reported the JCV index achieved 100 percent sensitivity but only 59 percent specificity as a PML predictor.10PubMed. PML risk stratification using anti-JCV antibody index and L-selectin That trade-off is intentional: the goal is to avoid missing anyone at elevated risk, even if it means many people with a high index will never develop PML. In fact, among patients flagged as high-risk by their index, about 99 percent will not develop PML.11PubMed. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy
Can Your JCV Status Change Over Time
Yes, and this catches many patients off guard. JCV serostatus is not fixed for life. In a large international cohort of over 1,000 natalizumab-treated patients, about 24 percent of those who were initially JCV negative became durably positive over the follow-up period, at a rate of roughly 7 percent per year. A smaller group, about 10 percent of initially positive patients, reverted to negative.12PubMed Central. High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients Another study in Turkish MS patients reported a similar annual seroconversion rate of about 6 percent and found that smokers, patients with a higher body mass index, and those who started natalizumab at age 35 or older converted more quickly.13PubMed. Anti-JCV antibody index seroconversion in Turkish multiple sclerosis patients treated with natalizumab
Because of this drift, patients on natalizumab who test JCV negative are typically retested every six months. A six-year longitudinal study found that about 17 percent of patients changed status during follow-up, and that baseline antibody index values helped predict who would stay positive or negative. An index above 0.90 strongly predicted remaining positive, while an index below 0.20 strongly predicted remaining negative.14PubMed Central. Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study If you are told you are “borderline” or your results have fluctuated near the cutoff, the most likely explanation is that your antibody levels sit close to the detection threshold, and small changes in immune activity nudge them above or below it.
How JCV Reactivates and Causes PML
While the virus is dormant, it carries a stable stretch of DNA called the archetype regulatory region. This form is harmless. When immune surveillance drops below a critical level, the virus undergoes genetic rearrangements in that regulatory region. These rearrangements turn the virus from a quiet bystander into something actively destructive.15American Journal of Neuroradiology. JC Virus Infection of the Brain The rearranged virus targets oligodendrocytes, the cells in the brain responsible for producing the myelin sheath around nerve fibers. As these cells are destroyed, patches of demyelination spread through the brain’s white matter.
Researchers have also found JCV DNA in bone marrow samples from both HIV-positive and HIV-negative individuals, and the viral sequences in bone marrow sometimes resemble the rearranged forms normally seen in the brains of PML patients.16PubMed Central. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation That finding suggests the rearrangement process may begin outside the brain, possibly in bone marrow or blood cells, before the virus migrates into the central nervous system. It is an active area of investigation and one of the reasons researchers are interested not only in the brain itself but also in the peripheral tissues where the virus hides.
Extended Interval Dosing to Reduce Risk
For JCV-positive MS patients who are doing well on natalizumab and do not want to switch therapies, one increasingly common strategy is extended interval dosing, or EID. Instead of receiving natalizumab infusions every four weeks (the standard interval), patients stretch the gap to roughly every five to eight weeks. The rationale is simple: longer gaps between doses may allow partial immune recovery in the brain between infusions, reducing the window for JCV to gain a foothold.
A large retrospective study of over 35,000 JCV-antibody-positive patients in the U.S. TOUCH prescribing database found that extended interval dosing was associated with a relative risk reduction for PML of 88 to 94 percent compared with standard dosing.17PubMed Central. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing That is a striking number, though the study was retrospective, and the patients who chose extended dosing may have differed from the standard-dosing group in ways that affected their risk. A subsequent systematic review and meta-analysis found no significant difference in MS disability progression or new brain lesions between the two dosing strategies, suggesting that extending the interval does not clearly sacrifice disease control, though the PML comparison was underpowered because the event is so rare in both groups.18PubMed. Efficacy and safety of extended-interval dosing of natalizumab in multiple sclerosis: a systematic review and meta-analysis with subgroup evaluation
Recognizing PML on Brain Imaging
Because PML can be difficult to distinguish from an MS relapse in its earliest stages, brain MRI plays a critical role in surveillance. Typical PML lesions start just beneath the cortex and spread inward into deeper white matter. On MRI they appear bright on certain sequences and dark on others, with a characteristic pattern: a sharp, well-defined border on the side facing the gray matter and a fuzzy, irregular edge on the side facing deeper white matter.19PubMed. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy Over time these lesions grow and can merge together, spreading through neural pathways.20PubMed Central. Development of demyelinating lesions in progressive multifocal leukoencephalopathy (PML): Comparison of magnetic resonance images and neuropathology of post-mortem brain
Catching PML early matters enormously for outcomes. One of the diagnostic challenges is that spinal fluid testing for JCV DNA can sometimes produce false-negative results, particularly when viral load is low in the early disease stage. A reported case documented a rapidly fatal PML in which the initial spinal fluid PCR came back negative despite high viral levels, and the diagnosis was only confirmed after testing targeted a different part of the viral genome.21PubMed Central. False negative PCR despite high levels of JC virus DNA in spinal fluid: Implications for diagnostic testing A recent review noted that this problem can create a false sense of certainty and delay diagnosis precisely when early intervention would help most.22PubMed. JC virus PCR assay reporting for PML: promises, perils, and pitfalls For patients on natalizumab, many neurologists now schedule regular MRI scans specifically designed to catch asymptomatic lesions before they cause noticeable symptoms.
What Happens If PML Develops
There is no antiviral drug that directly kills JCV. The mainstay of treatment is restoring the patient’s own immune system so it can fight the virus. In natalizumab-associated PML, the standard approach is plasma exchange, which rapidly clears the drug from the bloodstream and allows immune cells to re-enter the brain.23PubMed Central. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function In HIV-related PML, starting or optimizing antiretroviral therapy serves the same purpose by rebuilding immune cell counts.
In natalizumab-related PML, survival exceeds 70 percent after plasma exchange, though outcomes range widely from severe permanent disability to relatively mild deficits.24PubMed Central. Progressive Multifocal Leukoencephalopathy Therapy The prognosis depends heavily on how much brain damage has already occurred by the time the immune system is restored. This is why early detection through routine MRI surveillance in high-risk patients can be genuinely lifesaving.
One major complication of immune restoration is a phenomenon called immune reconstitution inflammatory syndrome, or IRIS. As the immune system floods back into the brain, it can mount an overly aggressive inflammatory response against JCV-infected tissue, causing paradoxical clinical worsening: seizures, swelling, and new neurological symptoms on top of the original PML damage. In one series of HIV-related cases, IRIS appeared anywhere from one week to 26 months after starting antiretroviral therapy.25PubMed Central. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids Treatment with corticosteroids can help manage the inflammation, though evidence for their benefit is mixed: in one literature review, clinical outcomes were similar whether patients received steroids or not.26Frontiers in Immunology. Immune Reconstitution Inflammatory Syndrome Unmasking or Worsening AIDS-Related Progressive Multifocal Leukoencephalopathy: A Literature Review
Experimental Treatments on the Horizon
Because PML still carries significant mortality and there is no targeted antiviral, researchers have been exploring adoptive T-cell therapy. The idea is to take virus-specific T cells from a healthy donor and infuse them into the PML patient to fight JCV on the patient’s behalf. An early proof-of-concept study treated three immunosuppressed PML patients with T cells originally raised against BK virus, a close relative of JCV. Two of the three showed clinical improvement and clearance of JCV from spinal fluid.27PubMed Central. Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy
A more recent study used directly isolated virus-specific T cells from partially matched donors and compared outcomes to a historical cohort treated with immune checkpoint inhibitors, where 56 percent of patients died within a year. The T-cell treated group showed a trend toward better survival, though the difference did not reach statistical significance.28JAMA Neurology. Directly Isolated Allogeneic Virus–Specific T Cells in Progressive Multifocal Leukoencephalopathy These therapies are still experimental and available mainly through specialized centers, but they represent the first time researchers have had something resembling a directed treatment for PML rather than just trying to rebuild the patient’s broader immune function.
JCV Can Cause More Than PML
PML gets most of the attention, but JCV is capable of causing a few other neurological conditions. Mutations in the virus can shift its preference from oligodendrocytes to other cell types. JCV granule cell neuronopathy, for instance, occurs when the virus infects a specific type of neuron in the cerebellum, causing progressive coordination problems without the large white-matter lesions typical of PML. JCV encephalopathy involves infection of cortical neurons and presents differently from classic PML. The virus has also been linked to meningitis.29PubMed Central. Novel syndromes associated with JC virus infection of neurons and meningeal cells: no longer a gray area30PubMed Central. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis These syndromes are rarer than PML, and they may be underrecognized because clinicians are not always looking for them.
The Anxiety of a Positive Result
Researchers have documented that MS patients who learn they are JCV seropositive experience significantly elevated anxiety about PML compared with those who test negative.31PubMed. Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients That anxiety is understandable: PML is frightening, and learning that you harbor the virus that causes it while taking a drug that could enable it creates a genuinely difficult psychological burden. But the numbers are worth keeping in perspective. Even among JCV-positive patients who have been on natalizumab for years and have a high antibody index, the vast majority never develop PML. The risk is real but small, and it is manageable through regular monitoring, retesting, antibody index tracking, and consideration of extended dosing or switching to an alternative therapy when the risk profile warrants it.
A Virus That Has Traveled with Humanity
JCV has a peculiar feature that sets it apart from most human viruses: its genetic subtypes map almost perfectly onto the geographic ancestry of the people it infects. Studies of JCV strains in Native American populations found that the large majority carried Asian-type subtypes, consistent with the migration of their ancestors from Asia across the Bering land bridge. Because the virus was already diversified into stable subtypes before those migrations, researchers have estimated that JCV may have been infecting humans for 50,000 to 100,000 years or more.32PubMed. Asian genotypes of JC virus in Native Americans and in a Pacific Island population: markers of viral evolution and human migration A more recent evolutionary analysis confirmed that JCV infected early human populations and traveled alongside our species during worldwide dispersal, adapting to the genetic background of different populations along the way.33Molecular Biology and Evolution. You Will Never Walk Alone: Codispersal of JC Polyomavirus with Human Populations
This deep evolutionary history helps explain why the virus is so widespread and so well-adapted to persisting quietly in human tissues. JCV did not recently jump from an animal host or emerge as a new threat. It has been part of the human condition for as long as modern humans have existed. The problems it causes are almost entirely a product of modern medicine’s ability to profoundly suppress the immune system, creating conditions the virus and its human host never naturally encountered together.